TY - Jour T1 - 严重哮喘管理：欧洲呼吸学会/美国胸部社会指南JF - 188bet官网地址欧洲呼吸期刊Jo - Eur Respir J Do - 10.1183 / 13993003.00588-2019 VL - 55是 - 1 SP - 1900588 Au - Holguin，FernandoAu - Cardet，Juan Carlos Au - Chung，Kian Fac - Diver，Sarah Au - Ferreira，Diogenes S. Au - Fitzpatrick，Anne Au - Gaga，Mina Au - Kellermeyer，Liz Au - Khurana，Sandhya Au - Knight，Shandra Au- 麦克唐纳，Vanessa M. Au - Morgan，Rebecca L. Au - 奥尔塔省，Victor E. Au - Rigau，David Au - Subbarao，Padmaja Au - Tonia，Thomy Au - Adcock，Ian M.Au - Bleecker，Eugene R. Au- Brighling，Chris Au - Boulet，Louis-Philippe Au - Cabana，Michael Au - Castro，Mario Au - Chanez，Pascal Au - 顾问，Adnan Au - Djukanovic，Ratko Au - Frey，urs Au - Frankemölle，Betty Au - Gibson，Peter Au - Hamerlijnck，Dominique Au - Jarjour，Nizar Au - Konno，Satoshi Au-Shen，Huahao Au - Pritical，Cathy Au - Bush，Andy Y1 - 2020 / 01/01/01/01/01/01 UR - //www.qdcxjkg.com/ content/55/1/1900588.Abstract n2 - 本文件为严重哮喘的管理提供了临床建议。综合证据合成，包括荟萃分析，总结了与欧洲呼吸协会/美国胸部社会工作队有关的所有可用证据。188bet官网地址使用成绩（建议，评估，开发和评估）方法等级评估了证据，结果总结了证据简介。讨论了证据合成并通过哮喘专家的多学科工作队制定的建议，他提出了关于六个具体问题的具体建议。在考虑到所需和不良后果的平衡后，证据质量，各种干预的可行性和可接受性，工作队提出了以下建议：1）建议使用抗白细胞蛋白（IL）-5和抗IL-5受体α对于严重的不受控制的成人嗜酸性嗜酸性哮喘表型; 2) suggest using a blood eosinophil cut-point ≥150 μL−1 to guide anti-IL-5 initiation in adult patients with severe asthma; 3) suggest considering specific eosinophil (≥260 μL−1) and exhaled nitric oxide fraction (≥19.5 ppb) cut-offs to identify adolescents or adults with the greatest likelihood of response to anti-IgE therapy; 4) suggest using inhaled tiotropium for adolescents and adults with severe uncontrolled asthma despite Global Initiative for Asthma (GINA) step 4–5 or National Asthma Education and Prevention Program (NAEPP) step 5 therapies; 5) suggest a trial of chronic macrolide therapy to reduce asthma exacerbations in persistently symptomatic or uncontrolled patients on GINA step 5 or NAEPP step 5 therapies, irrespective of asthma phenotype; and 6) suggest using anti-IL-4/13 for adult patients with severe eosinophilic asthma and for those with severe corticosteroid-dependent asthma regardless of blood eosinophil levels. These recommendations should be reconsidered as new evidence becomes available.The ERS/ATS Task Force makes recommendations on the use of novel therapies for severe asthma, specifically biologicals for type 2 high asthma, and antimuscarinic agents and macrolides, as well as on biomarkers for predicting treatment response http://bit.ly/2kZLRaD ER -